

# NYS Hepatitis C Elimination Data Summary: 2010-2021



New York State Hepatitis Elimination and Epidemiology Dataset



## **Primary HCV Elimination Metrics**

#### **HCV Diagnoses**

- <u>Definition</u> The number of persons newly diagnosed with HCV infection, per year.
- <u>Data Source</u> HEED
- <u>Goal</u> 90% of people living with HCV will be diagnosed

### **HCV** Treatment

- <u>Definition</u> The number of persons diagnosed with HCV with evidence of treatment for, or clearance of, HCV infection, per year.
- Data Sources
  HEED
- <u>Goal</u> 80% of diagnosed will be treated/clear infection

### New Infections among PWID

- <u>Definition</u> The rate and number of new HCV infections among PWID, per year.
- <u>Data Source</u> Annual survey of SEP clients to identify new HCV infections among PWID.
- <u>Goal</u> 80% reduction in new HCV infections

## **Diagnoses Metric**

- Tracks the number of individuals newly diagnosed with HCV infection, per year.
- Individuals with a positive HCV RNA test or genotype are considered to be diagnosed with HCV.
- Diagnosis numbers presented by geographic area, sex and age.
- Statewide diagnosis numbers compared to estimated yearly targets.







#### Rate of Hepatitis C Diagnoses\* by Sex, NYS: 2010-2021



in 2010-2011, may have been first diagnosed prior to 2010, resulting in the inflation of rates for these years.





in 2010-2011, may have been first diagnosed prior to 2010, resulting in the inflation of rates for these years.





YORK STATE of Health

### **Treatment/Clearance Metric**

- Tracks individuals diagnosed with HCV infection since 2010 who have evidence of treatment for, or clearance of HCV, per year.
- Individuals with a positive HCV RNA test or genotype followed by a subsequent HCV RNA negative test without any additional positive HCV RNA test or genotype tests, are considered to be treated or cleared of their HCV infection.
- Negative HCV RNAs reportable July, 2014 in NYC & Jan. 2016 statewide.
- Treatment/Clearance data presented by geographic area, sex and age





\* Diagnosed as indicated by a positive HCV RNA or genotype test since 2010.

\*\* Clearance of infection indicated if most recentHCV RNA or genotype result is negative. Clearance may occur following treatment or spontaneously, without treatment. Negative HCV RNA results reportable in NYC as of July 2014 and in NYS as of Jan. 2016.



#### Cumulative Percent of Persons Diagnosed\* with Hepatitis C Who Cleared\*\* Infection by Geographic Area and Year of Clearance, NYS: 2014 -2021



\* Diagnosed as indicated by a positive HCV RNA or genotype test since 2010.

\*\* Clearance of infection indicated if most recentHCV RNA or genotype result is negative. Clearance may occur following treatment or spontaneously, without treatment. Negative HCV RNA results reportable in NYC as of July 2014 and in NYS as of Jan. 2016.

#### Percent of Persons Diagnosed\* with Hepatitis C Who Cleared Infection\*\* by End of 2021, by Geographic Region, NYS



\* Diagnosed as indicated by a positive HCV RNA or genotype test since 2010.

\*\* Clearance of infection indicated if most recentHCV RNA or genotype result is negative. Clearance may occur following treatment or spontaneously, without treatment.



### Percent of Persons Diagnosed\* with Hepatitis C Since 2010 Who Cleared Infection\*\* by End of 2021, by Sex\*\*\* and Age at Diagnosis, NYS



\* Diagnosed as indicated by a positive HCV RNA or genotype test since 2010.

\*\* Clearance of infection indicated if most recent HCV RNA or genotype result is negative. Clearance may occur following treatment or spontaneously, without treatment.

\*\*\* Information on sex/gender is primarily obtained from laboratory reports, and may not reflect the gender identity of thedividual. Five individuals were reported as transgender.



## **New Infections Among PWID Metric**

### **Current Methodology**

Annual survey of PWID at SEPs

- Conducted at selected SEPs statewide
- Participants include SEP clients and non-SEP clients recruited using response driven sampling method and incentives.
- Questionnaire about injection drug using behaviors and access to HCV care.
- HCV testing (i.e., rapid antibody; RNA by dried blood spot (DBS))

HCV antibody avidity/recency assay

- PWID with detectable HCV RNA have a sample of the DBS used for the recency assay.
- Wadsworth conducted initial validation of the recency assay.



## **New Infections Among PWID Metric**

### **Proposed New Methodology**

### Adopt indicators described in 2022 Viral Hepatitis National Progress Report

Estimate new HCV infections in general population

- Start with number of acute HCV cases reported to NYS DOH and NYC DOHMH.
- Account for under ascertainment and underreporting by applying a multiplier.
- Each reported case of acute hepatitis C represents 13.9 estimated infections.

Track new HCV infections in PWID population

- Use observed acute case rates in the 18-40 age group as a proxy for new infections in the PWID population.
- The multiplier used to estimate new infections in the general population is NOT applied.



## **Summary of Data**

- Statewide, between 2010 and 2021, 189,749 people were diagnosed with HCV and 98,165 were cleared of their infection.
- Rates of HCV diagnoses are declining statewide, but since 2017 rates are higher in ROS than in NYC.
- Cumulative diagnoses from 2015-2021 are higher than the high-end estimated 2021 target.
- As of 2021, 51.7% of diagnosed people have cleared their infection (53.6% in NYC, 49.8% in ROS). The goal is to reach 80% by 2030.
- Treatment/clearance rates are increasing in all geographic regions, for all ages and for both males and females.



BLOG

RESOURCES

SIGN UP

16

### MEASURE O-



0

ABOUT~

The purpose of the HCV Dashboard is to **measure**, **track** and **disseminate** actionable information on progress towards **eliminating hepatitis C** as a public health problem in New York State.

## Hcvdashboardny.org

#### CONTACT

CUNY Institute for Implementation Science in Population Health 55 W 125th Street New York, NY 10027 info@hcvdashboardny.org



#### SIGN UP

Sign up for our latest updates about HCV in New York State:

DISSEMINATE

Email

Your email address

#### SIGN UP

#### FUNDED BY

DATA V

New York State Department of Health

#### **DESIGNED & DEVELOPED BY**

CUNY Institute for Implementation Science in Population Health

## **2021 Release of NYS Hep C Elimination Data Will Include:**

#### Diagnosis and Treatment/Clearance Metrics, Geographic & Demographic Stratifications: 2010-2021

		Age:			
		(<20, 10 Year			
		Age Groups,	Age:	Sex	Sex and Age in
Geographic Area	Total	70+)	(<40/40+)	(Male/Female)	Combination
Statewide	$\checkmark$	V		V	${f V}$ (excluding <20)
NYS (Excluding NYC)	$\checkmark$	V		V	${f V}$ (excluding <20)
Region (Excluding NYC)	$\checkmark$	V		V	$oldsymbol{V}$ (excluding <20)
County (Excluding NYC)	$\checkmark$		$\checkmark$	V	
NYC	$\checkmark$	V		V	$oldsymbol{V}$ (excluding <20)
NYC Borough	$\checkmark$	V		V	$oldsymbol{V}$ (excluding <20)
NYC Neighborhood					
Tabulation Area (NTA)	$\checkmark$				







17





### Hcvdashboardny.org



19



Cumulative Percent Treated/Cleared Among People





43.4 44.4 46.6 50.9 51.3 51.8 53.0 53.6 56.6







Cumulative Percent Treated/Cleared Among People Diagnosed With HCV

By borough · 2021











52.4 53.7 54.6 55.7 56.2